Editorials Sulfonylureas as second line treatment for type 2 diabetes BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3041 (Published 18 July 2018) Cite this as: BMJ 2018;362:k3041 Article Related content Metrics Responses Peer review Related articles Research Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study Published: 18 July 2018; BMJ 362 doi:10.1136/bmj.k2693 ResearchSulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events See more Cardiologist who fitted wrong pacemaker and destroyed patient notes is struck off BMJ August 23, 2019, 366 l5282; DOI: https://doi.org/10.1136/bmj.l5282 NICE rejects cannabidiol for two types of treatment resistant epilepsy in children BMJ August 23, 2019, 366 l5280; DOI: https://doi.org/10.1136/bmj.l5280 Risk of antibiotic resistant meningococcal infections in Hajj pilgrims BMJ August 23, 2019, 366 l5260; DOI: https://doi.org/10.1136/bmj.l5260 Polio: getting ready for the day after eradication BMJ August 23, 2019, 366 l5235; DOI: https://doi.org/10.1136/bmj.l5235 GP is struck off after writing to colleague’s patients claiming she had treated them inappropriately BMJ August 23, 2019, 366 l5278; DOI: https://doi.org/10.1136/bmj.l5278
